Clinical Trials Logo

Ischemic Optic Neuropathy clinical trials

View clinical trials related to Ischemic Optic Neuropathy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05353413 Recruiting - Optic Neuritis Clinical Trials

Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy.

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging

NCT ID: NCT03851562 Recruiting - Clinical trials for Ischemic Optic Neuropathy

Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy

PG-NAION
Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

Correction of the deficit in the perfusion pressure of the microcirculation that supplies the nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected to improve visual function in patients with ischemic optic neuropathy previous non-arteritic (NOIANA).

NCT ID: NCT03475173 Recruiting - Hemianopia Clinical Trials

New Non-invasive Modalities for Assessing Retinal Structure and Function

Start date: May 6, 2019
Phase: N/A
Study type: Interventional

This study investigates a new technology to assess the structure and function inside the eye. Retinal imaging of subjects with inner and outer retinal defects to detect areas of abnormal structure and function compared to other visual function tests.

NCT ID: NCT02377271 Recruiting - Clinical trials for Ischemic Optic Neuropathy

ENDOTHELION Study Group: Effect of Bosentan in NAION Patients

ENDOTHELION
Start date: August 2015
Phase: Phase 3
Study type: Interventional

Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after glaucoma in the population aged over 50 years. The visual prognosis of the condition is unfavorable in the great majority of cases, with significant effects on the visual field and vision. The severity of the unilateral condition is also associated with bilateralization in 15% at 5 years. There is no effective treatment for the acute phase of the disease or to reduce the rate of bilateralization. In this context, it is essential to develop new therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve damage.